EPS for Xencor, Inc. (XNCR) Expected At $-0.45; Putnam Fl Investment Management Co Trimmed By $886,464 Its Blackrock (BLK) Holding

April 18, 2018 - By Louis Casey

BlackRock, Inc. (NYSE:BLK) Logo

Analysts expect Xencor, Inc. (NASDAQ:XNCR) to report $-0.45 EPS on May, 8.They anticipate $0.14 EPS change or 45.16% from last quarter’s $-0.31 EPS. After having $-0.25 EPS previously, Xencor, Inc.’s analysts see 80.00% EPS growth. The stock increased 0.33% or $0.1 during the last trading session, reaching $30.72. About 228,060 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 17.37% since April 18, 2017 and is uptrending. It has outperformed by 5.82% the S&P500.

Putnam Fl Investment Management Co decreased Blackrock Inc. (BLK) stake by 3.4% reported in 2017Q4 SEC filing. Putnam Fl Investment Management Co sold 1,728 shares as Blackrock Inc. (BLK)’s stock rose 3.90%. The Putnam Fl Investment Management Co holds 49,105 shares with $25.23M value, down from 50,833 last quarter. Blackrock Inc. now has $84.66B valuation. The stock decreased 0.37% or $1.93 during the last trading session, reaching $524.91. About 544,443 shares traded. BlackRock, Inc. (NYSE:BLK) has risen 41.90% since April 18, 2017 and is uptrending. It has outperformed by 30.35% the S&P500.

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.31, from 0.9 in 2017Q3. It is positive, as 15 investors sold Xencor, Inc. shares while 28 reduced holdings. 15 funds opened positions while 37 raised stakes. 36.52 million shares or 1.10% more from 36.12 million shares in 2017Q3 were reported. 33,954 are held by Victory Cap Mngmt. Tiaa Cref Invest Limited Liability Corp holds 149,482 shares. 6.16M are held by Primecap Mgmt Ca. Blackrock Inc holds 3.12M shares or 0% of its portfolio. Equitec Specialists Ltd Llc holds 5,489 shares. Schwab Charles Invest Mgmt Inc accumulated 201,431 shares. Royal Bank Of Canada holds 0% or 1,567 shares. State Common Retirement Fund has 46,470 shares for 0% of their portfolio. The Washington-based Parametric Portfolio Assoc Ltd Liability Corporation has invested 0% in Xencor, Inc. (NASDAQ:XNCR). State Board Of Administration Of Florida Retirement Sys has 12,397 shares for 0% of their portfolio. Tower Limited Co (Trc) reported 474 shares. Amer Intl Grp Inc Inc accumulated 25,653 shares. D E Shaw & stated it has 0% in Xencor, Inc. (NASDAQ:XNCR). Fincl Bank Of Mellon Corporation has invested 0% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Deutsche Commercial Bank Ag holds 155,343 shares or 0% of its portfolio.

Since October 25, 2017, it had 2 insider buys, and 6 selling transactions for $146,630 activity. The insider Baracchini Edgardo Jr sold $1.24M. Foster Paul A sold $125,050 worth of stock or 5,000 shares. 150,000 Xencor, Inc. (NASDAQ:XNCR) shares with value of $2.97M were bought by STAFFORD JOHN S III.

Among 8 analysts covering Xencor (NASDAQ:XNCR), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Xencor had 21 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, February 28 by Cantor Fitzgerald. The stock has “Buy” rating by Leerink Swann on Wednesday, March 28. Zacks upgraded the shares of XNCR in report on Friday, September 4 to “Hold” rating. The rating was downgraded by Zacks on Saturday, August 8 to “Hold”. The rating was maintained by Piper Jaffray on Thursday, March 15 with “Buy”. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, October 4. Canaccord Genuity initiated it with “Buy” rating and $20 target in Tuesday, December 22 report. MLV maintained Xencor, Inc. (NASDAQ:XNCR) rating on Wednesday, August 5. MLV has “Buy” rating and $29 target. The rating was maintained by Wedbush on Monday, March 19 with “Outperform”. The firm earned “Buy” rating on Tuesday, November 28 by Cantor Fitzgerald.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $1.67 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

Investors sentiment decreased to 1.19 in 2017 Q4. Its down 0.19, from 1.38 in 2017Q3. It turned negative, as 42 investors sold BLK shares while 325 reduced holdings. 122 funds opened positions while 313 raised stakes. 129.61 million shares or 0.73% less from 130.57 million shares in 2017Q3 were reported. Blue Fincl has 3,984 shares for 1.19% of their portfolio. Mcrae Capital has 400 shares. Moreover, Junto Capital Mgmt LP has 6.62% invested in BlackRock, Inc. (NYSE:BLK) for 168,729 shares. Advisory Rech Inc reported 0.01% stake. Cubist Systematic Strategies Limited Liability owns 3,918 shares or 0.11% of their US portfolio. Braun Stacey Assoc Inc has 1.23% invested in BlackRock, Inc. (NYSE:BLK). Cibc Asset Management Incorporated accumulated 17,308 shares. Charter invested in 0.26% or 4,320 shares. Tctc Holdg accumulated 979 shares. Zevin Asset Ltd Liability Corporation invested in 2.45% or 21,040 shares. Cambridge Trust Com owns 39,814 shares for 1.29% of their portfolio. Blue Edge Ltd Co invested in 2,894 shares. Maltese Capital Management Limited Liability Co holds 0.29% or 7,400 shares. 33,313 were accumulated by Whittier Company. Beacon Cap holds 0% or 2 shares in its portfolio.

Among 18 analysts covering BlackRock (NYSE:BLK), 12 have Buy rating, 0 Sell and 6 Hold. Therefore 67% are positive. BlackRock had 89 analyst reports since August 26, 2015 according to SRatingsIntel. The rating was maintained by Argus Research with “Buy” on Tuesday, December 1. Deutsche Bank maintained it with “Buy” rating and $383 target in Thursday, June 16 report. Barclays Capital maintained BlackRock, Inc. (NYSE:BLK) rating on Wednesday, August 26. Barclays Capital has “Equal-Weight” rating and $337 target. Deutsche Bank maintained the stock with “Buy” rating in Thursday, October 15 report. Goldman Sachs downgraded the stock to “Neutral” rating in Wednesday, January 4 report. RBC Capital Markets maintained the shares of BLK in report on Thursday, January 21 with “Outperform” rating. Credit Suisse maintained it with “Buy” rating and $612.0 target in Thursday, October 12 report. The stock has “Outperform” rating by Credit Suisse on Friday, August 11. Barclays Capital maintained the stock with “Overweight” rating in Tuesday, October 10 report. The stock of BlackRock, Inc. (NYSE:BLK) has “Hold” rating given on Wednesday, October 7 by Jefferies.

Analysts await BlackRock, Inc. (NYSE:BLK) to report earnings on July, 16. They expect $6.73 earnings per share, up 28.44% or $1.49 from last year’s $5.24 per share. BLK’s profit will be $1.09 billion for 19.50 P/E if the $6.73 EPS becomes a reality. After $6.70 actual earnings per share reported by BlackRock, Inc. for the previous quarter, Wall Street now forecasts 0.45% EPS growth.

Putnam Fl Investment Management Co increased Schwab International Equity Et (SCHF) stake by 34,667 shares to 181,836 valued at $6.20 million in 2017Q4. It also upped Schwab U.S. Mid (SCHM) stake by 11,943 shares and now owns 37,908 shares. Ishares Core Msci Emerging Mar (IEMG) was raised too.

Xencor, Inc. (NASDAQ:XNCR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts